RxDoctor Payments Data

Srinivasa Eswarapu, MD

Internal Medicine · Belleville, NJNPI 1346215225

Payments from drug & device makers

$1,304in general payments, 2019–2025

Across 15 payments — averaging $86.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$495
  • Boehringer Ingelheim$281
  • AbbVie$249
  • GSK$125
  • Sanofi-aventis U.S. LLC$121
  • Merck$22
  • plus $12 from 1 others

What the payments were for

  • Food & beverage$1,27197%
  • Education$333%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,304 in reported general payments places this provider in the 70th percentile of 4,032 internal medicine providers in New Jersey.

See all internal medicine providers in New Jersey

Medicare billing

Part B allowed, 2024
$131,700
Medicare patients
91
Services billed
2,065

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin154$215,788
EliquisApixaban70$93,147
Breztri AerosphereBudesonide/Glycopyr/Formoterol64$68,114
JanuviaSitagliptin Phosphate46$53,194
JanumetSitagliptin Phos/Metformin Hcl44$47,410
EntrestoSacubitril/Valsartan32$44,952
TradjentaLinagliptin39$44,321
FarxigaDapagliflozin Propanediol30$43,503
MounjaroTirzepatide40$43,248
XareltoRivaroxaban22$35,572
JentaduetoLinagliptin/Metformin Hcl36$35,096
GlyxambiEmpagliflozin/Linagliptin16$27,468
Janumet XrSitagliptin Phos/Metformin Hcl21$20,284
VemlidyTenofovir Alafenamide13$18,844
Breo ElliptaFluticasone/Vilanterol27$18,555

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta, Jentadueto, Glyxambi, Jentadueto Xr$281$335,304259 claims
MerckJanuvia, Janumet, Janumet Xr$22$120,888111 claims
AstraZenecaBreztri Aerosphere, Farxiga$12$111,61794 claims
Johnson & JohnsonXarelto$495$35,57222 claims
GSKBreo Ellipta$125$18,55527 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 4,032 internal medicine providers in New Jersey.

Other internal medicine in Belleville

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →